{"prompt": "['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', 'All detailed clinical information regarding the rash, examination, treatment and', 'interpretation of the event needs to be reported on an SAE/EOSI report form as per', 'Section 12.1.5.1.', 'Blood taken for clinical chemistry, hematology including differential, and C3 level.', 'Table 5 outlines the clinical chemistry and hematology analytes to be assessed. If the', 'Investigator wishes more rapid results, a second set of blood tubes may be sent to the', 'local lab for faster processing.', 'Vital signs including temperature', 'Urine sent to local laboratory for urine eosinophils (if evaluation is available locally).', 'Subjects should be requested to undergo a standard dermatologic punch biopsy for', 'H&E staining and immunofixation. The biopsy should be of fresh lesion both for', 'diagnostic and scientific purposes, after obtaining specific informed consent. This', 'type of biopsy requires only antisepsis and local anesthesia, without the need for', 'sutures. The biopsy results will significantly help to clarify the underlying', 'pathophysiology of the rash and more fully inform the risk/benefit assessment and', 'ultimate therapeutic course. If the study site cannot perform a biopsy or any of the', 'above mandatory assessments (ie, photographs), then subjects should be referred to a', 'physician who can perform the assessments/biopsy (ie, a dermatologist). If a', 'non-study physician performs any of the assessments or biopsy, a full written', 'consultation report should be obtained expeditiously and include clinical examination', 'findings and clinical diagnostic assessment. Biopsies should be at least 3 mm', 'minimum diameter. Instructions for preparation of the samples and details regarding', 'histopathological assessment will be according to local practice. Note: If the rash is', 'no longer present by the time of medical evaluation, biopsy is not required.', 'If a subject with drug-related treatment-emergent maculopapular rash does not agree', 'to undergo skin punch biopsy, study drug dosing may be continued, but with weekly', 'visits until the rash has resolved.', 'Subjects will also be required to donate a blood sample for peripheral blood', 'mononuclear cells (PBMCs) for analysis of possible drug-specific immune responses', 'and possible drug-responsive T-cells. This sample should be obtained preferably 1 to', '3 months but as late as 5 years after occurrence of the rash. Information on PBMC', 'collection, processing, and shipment will be communicated to sites prior to sample', 'collection. All additional detailed clinical information regarding the rash,', 'examination, treatment and interpretation of the event needs to be reported on the', 'SAE/EOSI report form as per Section 12.1.5.1.', '11.2.15.', 'Adverse Events', 'AEs will be assessed and recorded from the time that the ICF is signed through the last follow-up', 'visit or until the AE is resolved or the subject is in a clinically stable condition with regards to', 'the AE. Full details on recording and reporting AEs are provided in Section 12.1.2.', '78']['Protocol', 'BioCryst Pharmaceuticals, Inc.', 'Version 3.0', 'CONFIDENTIAL', 'BCX7353-302', '11.3.', 'Patient-Reported Outcomes', 'The AE-QoL, TSQM, and WPAI will each be administered once at Baseline (predose) and at', 'Weeks 4, 8, 12, 18, 24, 28, 32, 36, 48, 60, 72, 84, and 96. After Week 96, the TSQM and WPAI', 'will be administered every 24 weeks (Weeks 120 and 144).', 'The EQ-5D-5L will be administered once at Baseline and at Weeks 4, 8, 12, 18, 24, 28, 32, 36,', '48, 60, 72, 84, and 96. After Week 96, the EQ-5D-5L will be administered every 24 weeks', '(Weeks 120 and 144). Subjects will fill out this questionnaire as instructed, describing their', 'current health state today. During the on-treatment visits (post-baseline), subjects will fill out a', 'second EQ-5D-5L questionnaire if they have had an attack since the previous visit. The subject', 'will be instructed to fill out this second questionnaire based on a recollection of their health state', 'during an average attack that they experienced since the previous visit.', 'Subjects will also be queried about their long-term experience on study beginning at Week 96', 'via brief long-term experience survey.', 'Each questionnaire will be translated into the local language as required. For all', 'subject-completed forms, clinic staff should ensure the subject reads the instructions and', 'completes the questionnaires in full prior to filing in the source documentation.', 'Where possible, the questionnaires should be completed by the subject prior to other assessments', 'for that visit to prevent influencing subject perceptions.', '11.4.', 'HAE Attack and Dosing Diary and Attack Confirmation', '11.4.1.', 'Screening and Parts 1 and 2', '11.4.1.1. HAE Attack and Dosing Diary', 'The Sponsor will supply e-diaries to sites. Study-specific manuals will be prepared for both site', 'staff and subjects for use of the e-diary for this study.', 'While a subject has an e-diary in their possession, the subject will fill out the HAE attack e-diary', 'daily, recalling whether or not symptoms of an HAE attack were experienced in the previous', '24 hours. Subjects will fill out the e-diary daily regardless of the presence of HAE symptoms. If', 'the subject does report an attack, additional details about the attack will be entered into the', 'e-diary including start and stop time of the attack, attack symptoms, anatomical location of', 'swelling (if applicable), severity, treatment(s) administered and times of administration, and', 'whether additional medical care was sought for the attack. During study drug administration,', 'subjects will also record the times of day study drug was taken daily in the e-diary.', 'All subjects will fill out an HAE e-diary during the run-in period of a minimum of 14 days to a', 'maximum of 56 consecutive days from the Screening visit to enable the qualifying attack rate to', 'be established. Subjects will continue to fill out their e-diary after the run-in period in advance of', 'the baseline visit, as applicable. Subjects will continue to fill out the e-diary daily during the', 'treatment and follow-up periods.', 'Site staff will set up the e-diary when a subject is initially provided an e-diary at the Screening', 'visit and then as needed during the study (eg, to turn off entry into the dosing diary when not', 'receiving study drug). Subjects should be instructed to bring their e-diary with them to each', '79']\n\n###\n\n", "completion": "END"}